BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company historical holders
total: 20
Dodge & Cox Stock Fund Bristol-Myers Squibb Company transactions over time
- Total transactions:
- 18
- New positions:
- 1
- Added:
- 4
- Reduced:
- 13
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
Dodge & Cox Stock Fund has been an institutional investor in Bristol-Myers Squibb Company (BMY) since 2019 Q3. According to 2026 Q1 report, Dodge & Cox Stock Fund holds 3,201,639 shares with a market value of roughly $194.18M representing 0.17% of their equity portfolio. The fund/company first acquired BMY in 2019 Q3, initially purchasing about 30.55M shares. Since the initial investment, Dodge & Cox Stock Fund has made 17 more transactions in this position.
Does Dodge & Cox Stock Fund still hold BMY?
Yes, Dodge & Cox Stock Fund continues to hold Bristol-Myers Squibb Company (BMY). According to their 2026 Q1 report, they maintain a position of 3,201,639 shares valued at approximately $194.18M, representing 0.17% of their equity portfolio.
When did Dodge & Cox Stock Fund first invest in BMY?
Dodge & Cox Stock Fund first invested in Bristol-Myers Squibb Company (BMY) in 2019 Q3 at the reported quarter-end price of $50.71 per share, acquiring 30,546,239 shares in their initial purchase.
What is Dodge & Cox Stock Fund's average cost basis for BMY?
Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for Bristol-Myers Squibb Company (BMY) is approximately $51.38 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $51.38
- Weighted AVG sell price:
- $59.86
BMY transactions history by Dodge & Cox Stock Fund
18 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.17%
|
3,201,639
|
$60.65
|
$194,179,405
|
-37.37% (-1,910,400)
|
-0.1%
|
|
2025 Q4
|
0.23%
|
5,112,039
|
$53.94
|
$275,743,384
|
-3.68% (-195,200)
|
-0.01%
|
|
2025 Q3
|
0.20%
|
5,307,239
|
$45.10
|
$239,356,479
|
-12.36% (-748,500)
|
-0.03%
|
|
2025 Q2
|
0.24%
|
6,055,739
|
$46.29
|
$280,320,158
|
-39.15% (-3,895,500)
|
-0.16%
|
|
2025 Q1
|
0.53%
|
9,951,239
|
$60.99
|
$606,926,067
|
-12.28% (-1,392,800)
|
-0.08%
|
|
2024 Q4
|
0.57%
|
11,344,039
|
$56.56
|
$641,618,846
|
-0.10% (-11,300)
|
-0%
|
|
2023 Q3
|
0.71%
|
11,355,339
|
$58.04
|
$659,063,876
|
+0.53% (+60,300)
|
+0%
|
|
2023 Q2
|
0.78%
|
11,295,039
|
$63.95
|
$722,317,744
|
+0.36% (+40,000)
|
+0%
|
|
2022 Q3
|
1.01%
|
11,255,039
|
$71.09
|
$800,120,723
|
-4.54% (-535,300)
|
-0.04%
|
|
2022 Q2
|
1.06%
|
11,790,339
|
$77.00
|
$907,856,103
|
-32.69% (-5,727,000)
|
-0.45%
|
|
2021 Q4
|
1.13%
|
$62.35
|
-3.74% (-680,000)
|
|||
|
2021 Q3
|
1.18%
|
$59.17
|
+0.92% (+165,600)
|
|||
|
2021 Q1
|
1.40%
|
$63.13
|
+9.49% (+1,562,900)
|
|||
|
2020 Q4
|
1.44%
|
$62.03
|
-0.16% (-27,000)
|
|||
|
2020 Q3
|
1.64%
|
$60.29
|
-1.19% (-198,200)
|
|||
|
2020 Q2
|
1.64%
|
$58.80
|
-20.37% (-4,269,200)
|
|||
|
2020 Q1
|
2.27%
|
$55.74
|
-31.37% (-9,583,000)
|
|||
|
2019 Q3
|
2.24%
|
$50.71
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.